CD99 dual behavior has been reported to be associated with tumor progression in Ewing sarcoma and acute lymphoblastic leukemia [21], as tumor suppressor in osteosarcoma [22], and in Hodgkin’s lymphoma [23], which may be attributed to differential preponderance of CD99 isoforms. This evidence concerns the gene CD99 and Hodgkins lymphoma.